banda transcan

The consortium of the new project: TRANSCAN-3 Sustained collaboration of national and regional programmes in cancer research, funded by the European Commission under Horizon 2020 from 2021 to 2026 (Grant Agreement no. 964264),

is pleased to announce its first Joint Transnational Call co-funded by the European Commission (JTC 2021) on the topic:

"Next generation cancer immunotherapy: targeting the tumour microenvironment"

28 funding organizations from 19 countries are participating.

The submission deadline for pre-proposals is 29th June 2021..
It is expected that consortia invited for the full-proposal stage will be asked to submit their proposal on November 2021.

read more and go to the call documents  

ERA-NET Cofund TRANSCAN-3: Sustained collaboration of national and regional programmes in cancer research

The TRANSCAN-3 network, with a strong background in funding cancer research (since 2011, with the previous projects TRANSCAN and TRANSCAN-2), embodies an excellent model of cross-national cooperation by bringing together funding organisations from several countries, with the common goal of supporting translational cancer research through cross-national joint calls for proposals, and by an efficient investment of dedicated national/regional public funding, leveraged with foundation/ charity-based resources and EU financial support.

Schermata 2021 03 25 alle 16.32.23

PARTNERS: The TRANSCAN-3 partners are 31 from 20 countries

Ministero della Salute (IT-MoH), Italy (Project Coordinator)
Istituto Superiore di Sanità (ISS), Italy
Fonds zur Förderung der wissenschaftlichen Forschung (FWF), Austria
Fonds de la Recherche Scientifique (F.R.S.-FNRS), Belgium
Fonds voor Wetenschappelijk Onderzoek – Vlaanderen (FWO), Belgium
Sihtasutus Eesti Teadusagentuur, (ETAg) Estonia
Fondation ARC pour la recherche sur le cancer (ARC), France
Institut National du Cancer (INCa), France
Bundesministerium für Bildung und Forschung (BMBF), Germany
Deutsches Zentrum für Luft- und Raumfahrt e. V. (DLR), Germany
Geniki Grammatia Erevnas kai Kainotomias (GSRI), Greece
Nemzeti Kutatási, Fejlesztési és Innovációs Hivatal (NKFIH), Hungary
The Health Research Board (HRB), Ireland
Chief Scientist Office, Ministry of Health (CSO-MOH), Israel
Alleanza contro il cancro (ACC), Italy
Fondazione regionale per la ricerca biomedica (FRRB), Italy
Ministero dell'Università e della Ricerca (MUR), Italy
Regione Toscana (TuscReg), Italy
Valsts izglītības attīstības aģentūra (VIAA), Latvia
Kreftforeningen (NCS), Norway
Norges Forksningsrad (RCN), Norway
Narodowe Centrum Badań i Rozwoju (NCBR), Poland
Fundação para a Ciência e a Tecnologia (FCT), Portugal
Unitatea Executiva pentru Finantarea Invatamantului Superior, a Cercetarii, Dezvoltarii si Inovarii (UEFISCDI), Romania
Slovenská akadémia vied (SAS), Slovakia
Fundación Científica de la Asociación Española contra el Cáncer (FCAECC), Spain
Fundación para el Fomento en Asturias de la Investigación Científica Aplicada y la Tecnología (FICYT), Spain
Instituto de Salud Carlos III (ISCIII), Spain
Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK), Turkey
Canadian Institutes of Health Research (CIHR), Canada
Ministry of Science and Technology (MoST), Taiwan


Cancer is a worldwide health burden and a major public health challenge. Despite significant advances in the understanding, prevention, diagnostics and treatment, cancer remains a public health problem in Europe and the world. In such a setting, translational cancer research plays a key role in successfully addressing the growing burden of cancer.

The great potential of translational cancer research in Europe will only be achieved when the main barriers are systematically addressed through concerted actions between public and private organisations that provide funds for research, researchers, healthcare providers and all those engaged in the cancer research spectrum. Moreover, adequate and systematic financial support backed by a strong political commitment is absolutely essential to help reduce the burden of cancer that European citizens are currently facing.

The TRANSCAN-3 project, building up on the well-established cooperation and accomplishments, through the harmonisation of national/regional funding mechanisms and programmes, plus continued and sustained series of efforts for the access to and sharing of data on cancer research, also aims at becoming a catalysts for a sustainable model of funding of high-impact cancer research in Europe and beyond, with an approach to effectively engage relevant stakeholders (patients, society as a whole, policy makers, etc.) in different stages of the action.

ERANET-TRANSCAN 3 is the continuation of ERA-NET TRANSCAN-2

The ERA-NET: Aligning national/regional translational cancer research programmes and activities - TRANSCAN-2 was a project funded by the European Commission under the EU framework programme Horizon2020 (Grant Agreement no. 643638) from 2015 to 2021.

It is the continuation of the previous ERA-NET on translational cancer research TRANSCAN, funded under the FP7 from 2011 to 2014.

TRANSCAN-2 is a collaborative network of ministries, funding agencies and research councils with programmes in translational cancer research. The network is composed of 31 partners from 20 Countries.

The project is coordinated by the Ministry of Health, Italy
Coordinator: Dr. Giovanni Leonardi. Deputy coordinator: Dr. Gaetano Guglielmi

Dr. Silvia Paradisi
Project Manager
Italian National Institute of Health
Viale Regina Elena, 299
00161 Rome, Italy
mail to:


 Announcement: JTC 2021
The new TRANSCAN-3 project consortium is launching the first Joint Transnational Call for proposals, co-funded by the European Commission, on:
"Next generation cancer immunotherapy: targeting the tumour microenvironment"

 Sustained collaboration of national and regional programmes in cancer research
is the new project funded by the European Commission under H2020  which started on 1st March 2021 and will last five years (G. A. no. 964264)

A TRANSCAN-2 brochure, highlighting key achievements, is available for download


eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 964264.